Pages that link to "Item:Q5427414"
From MaRDI portal
The following pages link to The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach (Q5427414):
Displaying 24 items.
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach (Q93669) (← links)
- On the consistency of the continual reassessment method with multiple toxicity constraints (Q499432) (← links)
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
- A phase I dose-finding study based on polychotomous toxicity responses (Q1708945) (← links)
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials (Q1929691) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Multivariate Markov models for the conditional probability of toxicity in phase II trials (Q2792772) (← links)
- Continual reassessment method for partial ordering (Q2893418) (← links)
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents (Q3183236) (← links)
- Continual reassessment method with multiple toxicity constraints (Q3303685) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- Risk-Group-Specific Dose Finding Based on an Average Toxicity Score (Q3576932) (← links)
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity (Q4548226) (← links)
- Simple benchmark for complex dose finding studies (Q5170208) (← links)
- A system for determining maximum tolerated dose in clinical trial (Q5880093) (← links)
- gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials (Q6068828) (← links)
- Generalized Bayes Quantification Learning under Dataset Shift (Q6110729) (← links)
- A continual reassessment method without undue risk of toxicity (Q6171847) (← links)
- Biomarker-based precision dose finding for immunotherapy combined with radiotherapy (Q6572286) (← links)
- TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes (Q6572287) (← links)
- CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome (Q6625779) (← links)
- On the properties of the toxicity index and its statistical efficiency (Q6627682) (← links)
- uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials (Q6627822) (← links)
- Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer (Q6636217) (← links)
